Medical Care Technologies Opens Volunteer Intake for Melanoma Scan Beta

Medical Care Technologies Inc. (OTCID: MDCE) has activated volunteer intake for its Melanoma Scan Beta, following the company's announcement on August 31, 2026. This move marks a significant step in the development of the AI-assisted imaging application, which aims to support the organization and longitudinal tracking of skin images.

The company had previously launched a first human-submitted dataset initiative, signaling its intention to move beyond reliance on established public cancer imaging datasets. This new phase, now open to volunteers, is designed to introduce real-world variability into the testing process. Volunteer-submitted images will help the company evaluate how the Melanoma Scan Beta performs with user-captured photographs, capturing conditions such as lighting, device type, distance, skin tone, and everyday image quality.

"The next step is now live," said Marshall Perkins, CEO of Medical Care Technologies. "We are beginning to collect the first human-submitted images that will help us test Melanoma Scan Beta under real-world conditions."

MDCE Melanoma Scan Beta is currently in beta-stage development and is not intended for clinical diagnosis. It is an AI-assisted application designed to support image organization, cataloging, and longitudinal tracking of visible skin images over time. The platform remains in development and has not received regulatory clearance.

"The objective is to evaluate how the system handles user-captured photographs in a real-world setting, as opposed to the standardized images found in public datasets," explained Perkins.

Participants in the volunteer intake process will contribute images for internal model evaluation, workflow testing, image intake review, body-map organization assessment, and longitudinal comparison functions. Any concerns about skin changes should be reviewed by a licensed clinician.

Medical Care Technologies Inc. continues to advance its AI vision capabilities across health, wellness, and enterprise imaging applications. The company, based in Mesa, Arizona, is a diversified technology firm focusing on the development and commercialization of AI-powered applications.

"Moving to this new phase is a critical step in our development process," Perkins stated. "We are excited to see how the real-world data will enhance the functionality of our Melanoma Scan Beta."

Investors and interested parties can learn more about Medical Care Technologies at https://www.medicalcaretechnologies.com.

SOURCE: Medical Care Technologies Inc.